SCHEMBL6038435

SCHEMBL6038435

Cc1ccc(S(=O)(=O)Nc2nccnc2OCc2ccccc2Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
CCR4 P51679 2/20 0.46
CCR2 P41597 1/20 0.46
ALDH1A1 P00352 4/20 0.46
POLB P06746 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
PIK3C2B O00750 1/20 0.44
PIK3C2G O75747 1/20 0.44
HPGD P15428 1/20 0.43
SLC40A1 Q9NP59 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
HIF1A Q16665 1/20 0.42
AR P10275 1/20 0.42
PTGS2 P35354 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038908 0.91 CCR4 (0.53) KMT2AMEN1CCR4CCR2ALDH1A1
SCHEMBL6038844 0.88 KMT2A (0.50) KMT2AMEN1ALDH1A1POLBL3MBTL1
SCHEMBL6038750 0.87 CCR4 (0.50) KMT2AMEN1CCR4CCR2ALDH1A1
SCHEMBL6038620 0.87 KMT2A (0.47) KMT2AMEN1CCR4CCR2ALDH1A1
SCHEMBL6038528 0.87 KMT2A (0.47) KMT2AMEN1CCR4CCR2ALDH1A1
SCHEMBL6038612 0.86 MEN1 (0.53) KMT2AMEN1CCR4MAPTSMN1; SMN2
SCHEMBL6038621 0.84 LMNA (0.51) KMT2AMEN1ALDH1A1POLBL3MBTL1
SCHEMBL6039107 0.84 KMT2A (0.46) KMT2AMEN1ALDH1A1POLBLMNA
SCHEMBL6038808 0.84 CCR4 (0.57) KMT2AMEN1CCR4ALDH1A1MAPT
SCHEMBL6038922 0.84 KMT2A (0.45) KMT2AMEN1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 KMT2A 4190/4885MEN1 2431/4885CCR4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.